Glenview State Bank Trust DEPT. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,814 shares of the company’s stock after selling 650 shares during the period. Johnson & Johnson makes up 4.8% of Glenview State Bank Trust DEPT.’s holdings, making the stock its 2nd largest position. Glenview State Bank Trust DEPT.’s holdings in Johnson & Johnson were worth $9,368,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the company. Lenox Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the period. Thomas J. Herzfeld Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $117,000. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares during the period. Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson during the first quarter valued at $186,000. Finally, Taylor Wealth Management Partners increased its position in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares during the period. Institutional investors own 66.06% of the company’s stock.
Shares of Johnson & Johnson (NYSE JNJ) traded up 0.01% on Friday, hitting $133.10. The stock had a trading volume of 4,270,571 shares. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The stock has a market cap of $357.24 billion, a P/E ratio of 22.52 and a beta of 0.78. The firm has a 50 day moving average of $133.09 and a 200 day moving average of $126.30.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the prior year, the company posted $1.74 earnings per share. Johnson & Johnson’s quarterly revenue was up 1.9% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
WARNING: “Glenview State Bank Trust DEPT. Has $9.37 Million Stake in Johnson & Johnson (JNJ)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://stocknewstimes.com/2017/08/12/glenview-state-bank-trust-dept-has-9-37-million-stake-in-johnson-johnson-jnj.html.
Several brokerages recently weighed in on JNJ. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 price target on the stock. in a report on Monday, May 8th. Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Finally, UBS AG reiterated a “buy” rating and issued a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $133.72.
In related news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.